Skip to main content
Fig. 2 | Pediatric Rheumatology

Fig. 2

From: Intravenous abatacept in Japanese patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study

Fig. 2

Time courses of JIA-ACR pediatric response rates and inactive disease rates from baseline to Week 52 of the cumulative period. The proportion of patients who achieved JIA-ACR30 (open circle), JIA-ACR50 (open triangle), JIA-ACR70 (open square), JIA-ACR90 (open diamond), and inactive disease (asterisk) was evaluated at indicated time points (all treated patients; N = 20). Data from Week 2 through Week 16 were analyzed with non-responder imputation (patients with missing data were considered as non-responders). Data from Week 20 through Week 52 were analyzed using observed cases (only patients who were in the study at the time point being evaluated). JIA-ACR30/50/70/90 Juvenile idiopathic arthritis-American College of Rheumatology criteria 30/50/70/90% improvement

Back to article page

Pediatric Rheumatology

ISSN: 1546-0096